Shots:

• The company initiates the P-IIa (PREVAIL-2) POC study to evaluate the efficacy & safety of PRV-3279 (q4w for 5mos.) vs PBO in ~100 patients with SLE across ~28 sites in the US & Hong Kong. The results are expected in 2024
• The 1EPs is to evaluate the ability of PRV-3279 to reduce SLE flare. The therapy was well-tolerated in a prior SAD in P-I study & MAD in P-Ib (PREVAIL-1) study, reduction in IgM production @8wks.
• The company collaborated with Hangzhou Zhongmei Huadong to develop & commercialize PRV-3279 in Greater China. PRV-3279 is a humanized bispecific DART molecule targeting CD32B & CD79B & has the potential to intercept the pathophysiology of SLE & B cell-mediated autoimmune diseases

Ref: PR Newswire | Image: Provention Bio